Iguratimod prevents renal fibrosis in unilateral ureteral obstruction model mice by suppressing M2 macrophage infiltration and macrophage–myofibroblast transition

Yueyuan Zhou,Zhilan Li,Shenyi Yu,Xuan Wang,Tingting Xie,Weiru Zhang

DOI: https://doi.org/10.1080/0886022x.2024.2327498

IF: 3.222

2024-04-27

Renal Failure

Abstract:Iguratimod is a novel synthetic, small-molecule immunosuppressive agent used to treat rheumatoid arthritis. Through ongoing exploration of its role and mechanisms of action, iguratimod has been observed to have antifibrotic effects in the lung and skin; however, its effect on renal fibrosis remains unknown. This study aimed to investigate whether iguratimod could affect renal fibrosis progression. Three different concentrations of iguratimod (30 mg/kg/day, 10 mg/kg/day, and 3 mg/kg/day) were used to intervene in unilateral ureteral obstruction (UUO) model mice. Iguratimod at 10 mg/kg/day was observed to be effective in slowing UUO-mediated renal fibrosis. In addition, stimulating bone marrow-derived macrophages with IL-4 and/or iguratimod, or with TGF-β and iguratimod or SRC inhibitors in vitro , suggested that iguratimod mitigates the progression of renal fibrosis in UUO mice, at least in part, by inhibiting the IL-4/STAT6 signaling pathway to attenuate renal M2 macrophage infiltration, as well as by impeding SRC activation to reduce macrophage–myofibroblast transition. These findings reveal the potential of iguratimod as a treatment for renal disease.

urology & nephrology

What problem does this paper attempt to address?

The paper aims to investigate the effects of Iguratimod on renal fibrosis in a unilateral ureteral obstruction (UUO) mouse model and explore its potential mechanisms. Specifically, the paper focuses on the following points:

1. **Renal Fibrosis Intervention Effect**: The study examined the impact of different concentrations of Iguratimod (30 mg/kg/day, 10 mg/kg/day, and 3 mg/kg/day) on the progression of renal fibrosis in the UUO mouse model. The results showed that a dose of 10 mg/kg/day could effectively slow down the renal fibrosis caused by UUO.

2. **Inhibition of M2 Macrophage Infiltration**: The research found that Iguratimod alleviates renal fibrosis by inhibiting the infiltration of M2 macrophages. M2 macrophages play a crucial role in the process of renal fibrosis, promoting the excessive production of extracellular matrix (ECM) components and the secretion of pro-fibrotic factors.

3. **Inhibition of Macrophage-to-Myofibroblast Transition (MMT)**: The paper also explored how Iguratimod reduces renal fibrosis by inhibiting the transition of macrophages to myofibroblasts. Myofibroblasts are one of the main cell types that produce ECM and play a key role in renal fibrosis.

4. **Molecular Mechanisms**:
- **IL-4/STAT6 Signaling Pathway**: Iguratimod reduces M2 macrophage infiltration by inhibiting the IL-4/STAT6 signaling pathway.
- **SRC Signaling Pathway**: Iguratimod also reduces the occurrence of MMT by inhibiting SRC activation.

5. **In Vitro Experiment Validation**: In in vitro experiments, Iguratimod was able to inhibit the polarization of bone marrow-derived macrophages (BMDMs) to M2 macrophages and suppress the TGF-β-induced MMT process.

These results suggest that Iguratimod has the potential to treat renal fibrosis, particularly showing significant effects in inhibiting M2 macrophage infiltration and the transition of macrophages to myofibroblasts.